Dr. Akindele E. Kolade, MD

Dr. Kolade practices at Cal Psychiatric Services in Las Vegas, Nevada.

Dr. Kolade's NPI, 1922051846, was assigned on May 19, 2006. Dr. Kolade holds California license A84300.

Dr. Kolade's primary practice is Cal Psychiatric Services, at 3201 S Maryland Pkwy, Las Vegas, NV 89109 in Clark County. The practice phone is (702) 629-7490.

Dr. Kolade's primary practice is Cal Psychiatric Services in Las Vegas, Nevada. Dr. Kolade is also affiliated with Smokey Point Behavioral Hospital. The medical group on file is Cal Psychiatric Services. Dmand AI also links Dr. Kolade to 6 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kolade practices, 2 sites in all. Vendor and product names are available with a free account.

Psychiatry is Dr. Kolade's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Dmand AI has Dr. Kolade's licenses on file in 2 states: California and Nevada.

CMS data shows 216 Medicare services from Dr. Kolade across 2 procedure codes in 2024, for 72 Medicare patients. Medicare paid $21,812 for them. Every service was in an office.

CMS counts 72 Medicare patients who saw Dr. Kolade in 2024. The largest group is 65 to 74, with 29 patients. 72% of them have high blood pressure, and 71% have arthritis. 38% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kolade's median patient age at 61, with 59% women.

In 2024, Dr. Kolade wrote 3,334 Medicare Part D claims for 170 patients. 97% of them were for generic drugs. CMS names the drug for 3,190 of them, across 63 drugs with 11 or more claims each, at $124,350 in total drug cost. In 2023, CMS named 3,598 claims across 64 drugs.

Dr. Kolade accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kolade as offering telehealth.

Dmand AI links Dr. Kolade to 2 clinical trials. Conditions studied include Schizophrenia and Schizophrenia Spectrum and Other Psychotic Disorders. Otsuka Pharmaceutical Development & Commercialization, Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Kolade that name 2 trials.

CMS Open Payments shows 228 general payments to Dr. Kolade from 29 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 51% of the total. Allergan Inc. paid the most, $5,076. It also lists 14 research payments totaling $38,496 from 2016 to 2025, naming 2 clinical trials.